Bioharvest Sciences, Inc. ( (BHST) ) has released its Q2 earnings. Here is a breakdown of the information Bioharvest Sciences, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioHarvest Sciences Inc. is a company leveraging its patented Botanical Synthesis technology to produce plant-based compounds for nutraceutical health products and as a contract development and manufacturing organization (CDMO). The company operates in the health and wellness sector, offering innovative solutions without the need to grow the underlying plant.
In its second quarter of 2025 financial report, BioHarvest Sciences Inc. announced a robust 41% year-over-year revenue growth, reaching $8.5 million. This growth was driven by strong sales in its core VINIA capsule business and new product launches, in line with management’s guidance.
Key financial highlights include a 65% increase in gross profit to $5.1 million, with gross margins expanding to 60%. The core VINIA capsule business grew by 28%, while new products saw a 100% increase. The company also secured a new CDMO contract and launched innovative products such as the VINIA Daily Chews 2X Formula.
Despite the positive revenue growth, BioHarvest reported a net loss of $4.0 million for the quarter, attributed to non-cash finance expenses and increased operating costs. The company remains focused on achieving adjusted EBITDA breakeven by the fourth quarter of 2025, with expectations of further revenue growth in the upcoming quarters.
Looking ahead, BioHarvest plans to expand its product offerings and CDMO services, aiming for profitable growth and innovation in the plant-based compounds market. Management is optimistic about the company’s future, with new initiatives set to enhance its market presence and financial performance.